导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.91% | 1428/4773 |
| 近一周 | -0.86% | 1921/5467 |
| 近一月 | -0.57% | 559/5421 |
| 近一季 | 1.75% | 720/5238 |
| 近半年 | 2.90% | 1117/4931 |
| 近一年 | -1.46% | 2843/4400 |
| 近两年 | 47.51% | 1564/2954 |
| 近三年 | 55.28% | 496/2253 |
| 成立以来 | 50.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.65% 1488/4961 |
-6.26% 3682/5312 |
- - |
- - |
| 2025 | 21.60% 2024/4813 |
11.93% 264/3635 |
2.38% 1605/4076 |
11.62% 3145/4524 |
-4.93% 3497/4813 |
| 2024 | 22.29% 384/3463 |
-0.51% 1121/2808 |
11.72% 28/3014 |
4.82% 2888/3129 |
4.96% 655/3463 |
| 2023 | 4.91% 211/2656 |
3.63% 1157/2280 |
4.42% 84/2385 |
-5.17% 1287/2515 |
2.22% 68/2655 |
| 2022 | 1.41% 32/2207 |
1.55% 99/1919 |
3.81% 1088/2016 |
-8.12% 170/2113 |
4.70% 518/2208 |
| 2021 | 5.48% 544/1822 |
10.00% 51/1255 |
0.55% 1093/1330 |
-1.32% 516/1466 |
-3.36% 1448/1822 |
| 2020 | -11.94% 994/1250 |
-13.86% 944/1028 |
-1.91% 1034/1067 |
-3.76% 1098/1164 |
8.30% 681/1184 |
| 2019 | - - |
- - |
- - |
- - |
3.94% 821/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 太平MSCI香港价值增强C VS. 长安沪深300非周期A(740101) |